Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2AAdenosine Receptor Antagonists for the Treatment of Parkinson’s Disease.

MLA

Xiaohu Zhang, et al. “Lead Optimization of 4-Acetylamino-2-(3,5-Dimethylpyrazol-1-Yl)-6-Pyridylpyrimidines as A2AAdenosine Receptor Antagonists for the Treatment of Parkinson’s Disease.” Journal of Medicinal Chemistry, vol. 51, no. 22, Nov. 2008, pp. 7099–110. EBSCOhost, https://doi.org/10.1021/jm800851u.

APA

Xiaohu Zhang, John E. Tellew, Zhiyong Luo, Manisha Moorjani, Emily Lin, Marion C. Lanier, Yongsheng Chen, John P. Williams, John Saunders, Sandra M. Lechner, Stacy Markison, Tanya Joswig, Robert Petroski, Jaime Piercey, William Kargo, Siobhan Malany, Mark Santos, Raymond S. Gross, Jenny Wen, & Kayvon Jalali. (2008). Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2AAdenosine Receptor Antagonists for the Treatment of Parkinson’s Disease. Journal of Medicinal Chemistry, 51(22), 7099–7110. https://doi.org/10.1021/jm800851u

Chicago

Xiaohu Zhang, John E. Tellew, Zhiyong Luo, Manisha Moorjani, Emily Lin, Marion C. Lanier, Yongsheng Chen, et al. 2008. “Lead Optimization of 4-Acetylamino-2-(3,5-Dimethylpyrazol-1-Yl)-6-Pyridylpyrimidines as A2AAdenosine Receptor Antagonists for the Treatment of Parkinson’s Disease.” Journal of Medicinal Chemistry 51 (22): 7099–7110. doi:10.1021/jm800851u.